Nature's Sunshine Products Inc. (NATR) Stock Price

NATRStock

$12.64−11.61%52W

Market Cap$222.41M

P/E11.39x

PEG Ratio2.00

Div yield—

Beta0.82

NATR Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-62.76%

Price vs S&P 500 (4W)-1.59%

PEG Ratio2.00

VGM Score56.60

P/E Ratio (Annual)11.39x

P/CF (Annual)6.30x

Book Value / Share (Quarterly)$9.61

P/TBV (Annual)1.34x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)4.40%

Cash Flow / Share (Quarterly)$1.03

Price vs S&P 500 (YTD)-53.35%

Gross Margin (TTM)73.16%

Net Profit Margin (TTM)3.68%

EPS (TTM)$1.00

10-Day Avg Trading Volume0.10M

EPS Excl Extra (TTM)$1.00

Revenue Growth (5Y)4.50%

EPS (Annual)$1.06

ROI (Annual)12.08%

Gross Margin (Annual)72.42%

Net Profit Margin (5Y Avg)3.11%

Cash / Share (Quarterly)$4.68

P/E Basic Excl Extra (TTM)12.29x

Revenue Growth QoQ (YoY)1.95%

EPS Growth (5Y)-0.15%

P/E Normalized (Annual)11.39x

ROA (Last FY)7.48%

Revenue Growth TTM (YoY)6.77%

EBITD / Share (TTM)$2.36

ROE (5Y Avg)8.96%

Operating Margin (TTM)5.96%

Cash Flow / Share (Annual)$1.65

P/B Ratio1.31x

P/B Ratio (Quarterly)2.26x

Net Income / Employee (Annual)$24,200

EV / Revenue (TTM)0.28x

Net Interest Coverage (TTM)12.04x

ROA (TTM)6.91%

EPS Growth QoQ (YoY)-31.40%

EV / EBITDA (TTM)3.28x

EPS Incl Extra (Annual)$1.06

Current Ratio (Annual)2.28x

Quick Ratio (Quarterly)1.40x

3-Month Avg Trading Volume0.15M

52-Week Price Return-11.61%

EV / Free Cash Flow (Annual)4.85x

P/E Incl Extra (TTM)12.29x

Revenue / Employee (TTM)$610,500

Tangible BV / Share (Quarterly)$7.49

P/S Ratio (Annual)0.46x

Asset Turnover (Annual)1.84x

52-Week High$28.14

Operating Margin (5Y Avg)5.09%

EPS Excl Extra (Annual)$1.06

CapEx CAGR (5Y)5.71%

Tangible BV CAGR (5Y)0.65%

26-Week Price Return-52.85%

Quick Ratio (Annual)1.30x

13-Week Price Return-38.13%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)2.60x

Enterprise Value$139.90M

Revenue / Share Growth (5Y)6.18%

Asset Turnover (TTM)1.88x

Book Value / Share Growth (5Y)3.19%

Revenue / Employee (Annual)$595,700

Inventory Turnover (Annual)2.07x

Pretax Margin (Annual)6.21%

Cash / Share (Annual)$5.36

3-Month Return Std Dev44.73%

Gross Margin (5Y Avg)71.96%

Net Income / Employee (TTM)$22,500

EBITDA CAGR (5Y)3.66%

EBITDA Interim CAGR (5Y)-6.50%

ROE (Last FY)12.08%

Net Interest Coverage (Annual)9.98x

EPS Basic Excl Extra (Annual)$1.06

P/FCF (TTM)7.71x

Receivables Turnover (TTM)36.60x

EV / Free Cash Flow (TTM)7.74x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$1.00

Receivables Turnover (Annual)53.12x

ROI (TTM)11.00%

P/S Ratio (TTM)0.45x

Pretax Margin (5Y Avg)5.12%

Revenue / Share (Annual)$26.00

Tangible BV / Share (Annual)$6.63

Forward P/E11.24x

Free OCF CAGR (5Y)-2.51%

Price vs S&P 500 (52W)-27.14%

P/E Ratio (TTM)12.29x

EPS Growth TTM (YoY)34.10%

Year-to-Date Return-41.43%

5-Day Price Return-0.55%

EPS Normalized (Annual)$1.06

ROA (5Y Avg)5.54%

Net Profit Margin (Annual)4.07%

Month-to-Date Return-0.39%

Cash Flow / Share (TTM)$1.07

EBITD / Share (Annual)$2.09

EPS Growth (3Y)-34.26%

Operating Margin (Annual)5.15%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)8.13x

ROI (5Y Avg)8.90%

P/E Excl Extra (TTM)12.29x

LT Debt / Equity (Quarterly)0.01x

EPS Basic Excl Extra (TTM)$1.00

P/TBV (Quarterly)1.54x

P/B Ratio (Annual)2.34x

Inventory Turnover (TTM)1.87x

Pretax Margin (TTM)5.83%

Book Value / Share (Annual)$9.23

Price vs S&P 500 (13W)-40.82%

Net Margin Growth (5Y)-5.95%

Beta0.82x

P/FCF (Annual)7.71x

Revenue / Share (TTM)$26.83

ROE (TTM)11.00%

52-Week Low$12.00

vGradeA

gGradeC

mGradeC

vgmGradeC

NATR Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	$0.27	$0.21	-22.22%(-$0.06)
Q1 2026	May 7, 2026	$0.20	$0.30	+46.34%(+$0.10)
Q4 2025	Mar 10, 2026	$0.18	$0.30	+62.16%(+$0.11)
Q3 2025	Nov 6, 2025	$0.16	$0.36	+125.00%(+$0.20)
Q2 2025	Jul 31, 2025	$0.16	$0.35	+118.75%(+$0.19)

NATR Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.13

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
NATRNature's Sunshine Products Inc.	A	C	C	0.5x	6.8%	73.2%	-0.1%	$12.64
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Nature's Sunshine Products Inc.

Nature's Sunshine Products Inc manufactures and sells nutritional supplements and personal care products targeting weight management, cardiovascular health, digestive wellness, immune support, and general health. The company operates across Asia, Europe, North America, and Latin America, with Asia serving as its largest revenue market.

NATR Next Earnings Report

Report dateNov 9, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate$0.27

Revenue estimate$129.50M

Also reporting on Nov 9, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

NATR Insider Transactions

BuyAug 17, 2026
PRESCOTT GROUP CAPITAL MANAGEMENT L L C
Beneficial Owner of more than 10% of a Class of Security
Shares: 20,000Value: $293,800
BuyAug 10, 2026
PRESCOTT GROUP CAPITAL MANAGEMENT L L C
Beneficial Owner of more than 10% of a Class of Security
Shares: 141,389Value: $2.32M

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for August 2026

Companies in Related Industries

PTNMPitanium Limited Class A Ordinary sharesCosmetics & Toiletries
CABACabaletta Bio, Inc. Common StockBiological Products
IKTInhibikase Therapeutics, Inc. Common StockBiological Products
SABSSAB Biotherapeutics, Inc. Common StockBiological Products
LXEOLexeo Therapeutics, Inc. Common StockBiological Products
FATEFate Therapeutics, Inc.Biological Products
PLXProtalix BioTherapeutics, Inc. Common StockBiological Products
ALECAlector, Inc. Common StockBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.1

Buy

Consensus rating

52-Week Range

Low$12.00

High$28.14